What do systematic reviews say?

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

The review found no eligible studies for this question.

• PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in overall survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

• PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 0.99 [0.98, 1]
  1 study · 1857 participants
  Moderate

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

• PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 239 participants
  Moderate